InMed Pharmaceuticals Inc. (INM): ANSOFF-Matrixanalyse

In der dynamischen Landschaft der pharmazeutischen Innovation erweist sich InMed Pharmaceuticals Inc. als bahnbrechende Kraft, die sich strategisch durch die komplexe Welt der Cannabinoid-basierten Therapeutika bewegt. Durch die sorgfältige Ausarbeitung einer umfassenden Ansoff-Matrix stellt das Unternehmen eine mutige Roadmap vor, die Marktdurchdringung, Entwicklung, Produktinnovation und strategische Diversifizierung umfasst – und verspricht, das Gesundheitswesen durch modernste Cannabinoid-Technologien zu revolutionieren. Tauchen Sie ein in diese Erkundung des visionären Ansatzes von InMed, bei dem wissenschaftliche Präzision auf transformatives Potenzial trifft.

InMed Pharmaceuticals Inc. (INM) – Ansoff-Matrix: Marktdurchdringung

Erweitern Sie die Sichtbarkeit klinischer Studien und die Patientenrekrutierung

InMed Pharmaceuticals führte im Jahr 2022 zwei aktive klinische Studien durch, die sich auf Cannabinoid-basierte Therapieprogramme konzentrierten. Daten zur Patientenrekrutierung zeigten, dass 47 Teilnehmer an Studien zu Epidermolysis bullosa und Glaukom teilnahmen.

Steigern Sie die Marketingbemühungen für medizinisches Fachpersonal

Das Marketingbudget für 2022 belief sich auf 1,2 Millionen US-Dollar und war auf medizinische Fachkonferenzen und professionelle Netzwerke ausgerichtet.

• Teilnahme an 7 internationalen medizinischen Konferenzen
• Durchführung von 12 gezielten Webinaren
• Verteilte 5.000 professionelle Informationspakete

Fertigungsprozesse optimieren

Initiativen zur Senkung der Herstellungskosten führten im Jahr 2022 zu einer Verbesserung der Produktionseffizienz um 18 %.

Strategische Partnerschaften stärken

Etablierte Partnerschaften mit 3 Forschungseinrichtungen im Jahr 2022.

• Forschungskooperation mit der University of British Columbia
• Cannabinoid-Forschungsprogramm der Stanford University
• Klinische Studienpartnerschaft der Toronto Metropolitan University

Gesamtinvestition in die Forschungspartnerschaft: 850.000 US-Dollar im Jahr 2022.

InMed Pharmaceuticals Inc. (INM) – Ansoff-Matrix: Marktentwicklung

Zielen Sie mit etablierten Regulierungswegen für Cannabinoid-basierte Therapeutika auf internationale Märkte

InMed Pharmaceuticals hat wichtige internationale Märkte mit fortschrittlichen Cannabinoid-Regulierungsrahmen identifiziert:

Entdecken Sie die Expansion in Schwellenländer

Potenzielle Schwellenländer mit sich weiterentwickelnden Cannabisvorschriften:

• Deutschland: Der Markt für medizinisches Cannabis wird bis 2025 auf 1,5 Milliarden US-Dollar geschätzt
• Israel: Marktpotenzial für medizinisches Cannabis in Höhe von 300 Millionen US-Dollar
• Thailand: Erstes asiatisches Land mit umfassender medizinischer Cannabisgesetzgebung

Entwickeln Sie strategische Kooperationen

Aktuelle Pharma-Vertriebspartnerschaften:

Umfassende Marktforschung

Zielen Sie auf Gesundheitssegmente mit erheblichem Marktpotenzial:

• Dermatologie: 23,6 Milliarden US-Dollar Weltmarkt bis 2027
• Augenheilkunde: Marktpotenzial von 62,4 Milliarden US-Dollar
• Schmerztherapie: 87,2 Milliarden US-Dollar Weltmarkt bis 2026

InMed Pharmaceuticals Inc. (INM) – Ansoff Matrix: Produktentwicklung

Fortschrittliche Forschungspipeline für seltene Hauterkrankungen und neurologische Erkrankungen

InMed Pharmaceuticals hat sich auf die Entwicklung Cannabinoid-basierter Therapien für seltene Krankheiten konzentriert. Im vierten Quartal 2022 hatte das Unternehmen drei primäre Arzneimittelkandidaten in seiner Forschungspipeline.

Entwickeln Sie neuartige Mechanismen zur Arzneimittelabgabe

InMed hat im Jahr 2022 2,3 Millionen US-Dollar in die Entwicklung proprietärer Arzneimittelverabreichungstechnologien investiert.

• Forschung zu topischen Cannabinoid-Formulierungen
• Fortschrittliche transdermale Verabreichungssysteme
• Plattformen für die gezielte Verabreichung neurologischer Medikamente

Investieren Sie in fortschrittliche Forschungsplattformen

Forschungs- und Entwicklungsausgaben für 2022: 4,7 Millionen US-Dollar.

Verbessern Sie Ihr Portfolio an geistigem Eigentum

Im Dezember 2022 verfügte InMed weltweit über 12 aktive Patentanmeldungen.

• 6 Patente für Mechanismen zur Cannabinoidabgabe
• 4 Patente für therapeutische Anwendungen bei seltenen Krankheiten
• 2 Patente für neuartige Arzneimittelformulierungstechniken

InMed Pharmaceuticals Inc. (INM) – Ansoff-Matrix: Diversifikation

Mögliche Anwendungen von Cannabinoid-Technologien in angrenzenden Gesundheitssektoren

InMed Pharmaceuticals meldete für das vierte Quartal 2022 Forschungs- und Entwicklungskosten in Höhe von 3,2 Millionen US-Dollar. Die Cannabinoid-Technologieplattform des Unternehmens konzentriert sich auf Anwendungen in der Dermatologie und Neurologie.

Strategische Investitions- und Akquisitionsmöglichkeiten

Der Barmittelbestand von InMed belief sich zum 31. Dezember 2022 auf 11,6 Millionen US-Dollar und ermöglichte potenzielle Investitionen im Biotechnologiebereich.

• Budget für Biotechnologie-Akquisition: Ungefähr 5–7 Millionen US-Dollar
• Zielsektoren: Therapeutika für seltene Krankheiten
• Investitionskriterien: Unternehmen im präklinischen Stadium

Mögliche Spin-off-Forschungsinitiativen

Möglichkeiten der Technologielizenzierung

Das Patentportfolio von InMed umfasst 12 erteilte Patente in mehreren Gerichtsbarkeiten.

• Potenzielle Lizenzeinnahmen: 2–4 Millionen US-Dollar pro Jahr
• Zielunternehmen: Top 20 Pharmaunternehmen
• Lizenzschwerpunkt: Cannabinoid-basierte Therapietechnologien

InMed Pharmaceuticals Inc. (INM) - Ansoff Matrix: Market Penetration

The BayMedica commercial segment realized sales of $4.9M for the fiscal year ended June 30, 2025. This represented an increase of $0.34M, or 8%, compared to the fiscal year ended June 30, 2024.

For the three months ended March 31, 2025, BayMedica generated revenues of $1.26 million, matching the 8% growth rate seen for the full fiscal year 2025 period.

The broader market context for minor cannabinoid-infused edibles showed a 47% year-over-year growth in 2023, totaling $391 million in sales across ten regulated states.

The company's cash position as of June 30, 2025, was $11.1M, which supports funding planned operating expenses into the fourth quarter of calendar year 2026, depending on BayMedica revenues.

The following table summarizes the recent financial performance of the BayMedica commercial segment to frame the market penetration goals:

Actions to drive sales beyond the 8% fiscal 2025 growth rate include specific commercial strategies:

• Offer aggressive volume-based pricing to secure larger B2B supply contracts.
• Expand direct sales force coverage to capture more US health and wellness ingredient customers.
• Launch targeted digital campaigns emphasizing BayMedica's proprietary manufacturing quality.
• Target a revenue increase exceeding the $0.34M achieved between fiscal 2024 and fiscal 2025.

The proprietary manufacturing quality is supported by the development of a robust pilot-scale process for THCV production.

The company's stock price as of October 31, 2025, was $1.88, with a market capitalization of $4.48M.

InMed Pharmaceuticals Inc. (INM) - Ansoff Matrix: Market Development

You're looking at how InMed Pharmaceuticals Inc. can take its existing rare cannabinoid ingredients and commercial structure, BayMedica, and push them into new geographic areas or new customer types. This is Market Development, and it needs cash to fund the expansion efforts.

Initiate regulatory filings to commercialize rare cannabinoids in key European Union markets.

The ability to fund the necessary regulatory steps for EU market entry is supported by the balance sheet as of the end of fiscal year 2025. InMed had $11.1 million in cash, cash equivalents, and short-term investments on June 30, 2025. This cash position is expected to fund planned operating expenses and capital expenditures into the fourth quarter of calendar year 2026. The company recorded a net loss of $8.2 million for the year ended June 30, 2025.

Secure distribution partnerships to introduce BayMedica products into Asian functional food sectors.

The foundation for this expansion is the existing commercial business, BayMedica. For the year ended June 30, 2025, the BayMedica segment realized sales of $4.9 million. This represented an increase of $0.34 million, or 8%, compared to the year ended June 30, 2024. The business generates approximately 40 percent gross margins selling to the global health and wellness ingredient markets.

Target new B2B segments like high-end cosmeceuticals with existing rare cannabinoid ingredients.

Expanding into higher-value B2B segments like cosmeceuticals requires demonstrating the commercial viability of the current product line. The BayMedica Commercial segment reported an 8% increase in sales for the three months ended March 31, 2025, compared to the same period in 2024. However, the cost of sales for that segment increased by 23% for the same period, primarily due to an increase in sales of lower margin products. The overall annual revenue for fiscal year 2025 ending June 30, 2025, was $4.94 million, a 7.5% increase year-over-year.

Present BayMedica's commercial portfolio at international trade shows to find new global buyers.

Trade show presence is a direct sales and marketing cost that needs to be weighed against revenue generation. For the quarter ending September 30, 2025 (Q3 2025), revenue was reported at $1.12 million, which was up 11.43% year-over-year. The trailing twelve months ending September 30, 2025, showed total revenue of $4.80 million.

Here's a quick look at the key financial metrics supporting the commercial arm's ability to fund market development activities:

The performance of the BayMedica segment in fiscal 2025 shows a clear, albeit modest, growth trajectory:

• BayMedica segment sales growth for FY2025: 8%.
• Q1 2025 sales increase year-over-year: 8%.
• Q3 2025 sales year-over-year increase: 11.43%.
• Q3 2025 sales quarter-over-quarter change: down 14.1%.
• Increase in Cost of Sales for Q1 2025: 23%.

InMed Pharmaceuticals Inc. (INM) - Ansoff Matrix: Product Development

You're looking at the core of InMed Pharmaceuticals Inc.'s (INM) growth engine-the product pipeline-which is squarely in the Product Development quadrant of the Ansoff Matrix. This means maximizing value from existing markets (pharmaceutical indications) by bringing new or improved products to them.

For INM-901, targeting Alzheimer's disease (AD), the focus has shifted to the final preclinical steps before human trials. As of November 2025, the company announced the successful completion of pharmacokinetic studies in large animal models for the oral formulation. This is a major step, as the data demonstrated robust bioavailability over a seven-day dosing period. The next required action is advancing into Investigational New Drug (IND)-enabling studies, which is being supported by preparing for a pre-IND meeting with the U.S. Food and Drug Administration (FDA) and completing Chemistry, Manufacturing, and Controls (CMC) development to scale supply.

The financial underpinning for this work is clear. InMed reported a cash balance of \$11.1M as of June 30, 2025. A portion of this balance is earmarked for optimizing the oral formulation of INM-901, which is a critical activity preceding IND-enabling studies. This cash position is expected to support planned operating expenses and capital expenditures into the fourth quarter of calendar year 2026.

For INM-089, targeting dry Age-related Macular Degeneration (AMD), the preclinical work is being finalized to prepare for a first-in-human trial. The company selected an intravitreal (IVT) formulation for continued development in February 2025. This IVT formulation showed successful delivery in preclinical studies at doses up to 10 times the calculated safety margin relative to the therapeutic dose level. Furthermore, a series of dose-ranging in vivo studies were recently completed, with the resulting information guiding the selection of doses for pivotal preclinical toxicology studies, which are the next step toward an IND filing.

The development of INM-755 for Epidermolysis Bullosa (EB) is currently focused on securing external funding to move into Phase 3, as the Phase 2 trial is complete. The company is actively seeking strategic pharmaceutical partners to fund and advance this program.

Here is a snapshot of the key development activities and financial context:

The allocation of capital directly supports these product advancements. The investment into optimizing the oral formulation of INM-901 is a direct use of the company's liquidity.

• Cash balance as of June 30, 2025: \$11.1M.
• Expected cash runway into: Q4 2026.
• INM-901 optimization is a planned use of a portion of this cash.
• INM-901 preclinical work included a seven-day dosing study.

To be fair, the path from completing PK studies to starting IND-enabling studies requires rigorous documentation and regulatory alignment. Finance: finalize the budget allocation for INM-901 formulation optimization by next Tuesday.

InMed Pharmaceuticals Inc. (INM) - Ansoff Matrix: Diversification

Initiate a new drug discovery program targeting a novel, high-unmet-need oncology indication.

The current pharmaceutical focus includes INM-901 for Alzheimer's disease and INM-089 for dry Age-related Macular Degeneration, both proprietary small molecule drug candidates. The cash position as of June 30, 2025, was $11.1M, with an expected runway into the fourth quarter of calendar year 2026. This cash level must support the advancement of existing programs while funding a new oncology initiative.

Acquire a complementary small-molecule platform outside of the current CB1/CB2 receptor focus.

InMed Pharmaceuticals Inc.'s existing pipeline is noted for targeting the CB1/CB2 receptors. Diversification here would mean adding a platform that operates outside this established mechanism. The fiscal year 2025 net loss was $8.2M, compared to $7.7M in the prior year. Any acquisition would need to be financed against this current burn rate and cash reserve.

Leverage the IntegraSyn manufacturing technology to produce non-cannabinoid, high-value Active Pharmaceutical Ingredients (APIs).

The IntegraSyn system was developed to produce pharmaceutical-grade, bio-identical cannabinoids, achieving a cannabinoid yield of 5 g/L. To pivot this technology to non-cannabinoid APIs would require retooling or proving the modularity of the process for different substrates. Research and development expenses for the year ended June 30, 2025, totaled $2.9M.

Establish a joint venture with a major biotech firm to co-develop a new therapeutic in a non-CNS/Ocular market.

Current pharmaceutical development is centered on CNS (Alzheimer's) and Ocular (AMD) indications. A joint venture outside these areas represents a significant market diversification. BayMedica, the commercial segment, realized sales of $4.9M for the year ended June 30, 2025, an increase of 8% year-over-year. This commercial revenue stream provides a financial base, though General and administrative expenses rose to $6.6M in FY2025 from $5.8M in FY2024.

Here's the quick math on recent financial performance:

The current pipeline focus areas and associated data points are:

• INM-901 targets Alzheimer's disease pathology.
• INM-089 demonstrated neuroprotection in dry Age-related Macular Degeneration.
• IntegraSyn achieved a cannabinoid yield of 5 g/L.
• Cash on hand as of June 30, 2025, was $11.1M.
• Market Capitalization as of May 2025 was $2.83M.